Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alkaline phosphatase to reduce SIRS in COVID-19 with acute respiratory insufficiency
2020-001714-38Phase 2Active
- Sponsor
- Rode Kruis Ziekenhuis
- Start
- Nov 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of bovine intestinal alkaline phosphatase in coronavirus disease 2019 (COVID-19), Systemic Inflammatory Response Syndrome (SIRS), acute respiratory decompensation and 1 more, sponsored by Rode Kruis Ziekenhuis. Primary endpoint: Duration of mechanical ventilation. Started Nov 2020; status: active.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
coronavirus disease 2019 (COVID-19)Systemic Inflammatory Response Syndrome (SIRS)acute respiratory decompensationacute kidney failure (AKF)
Beyond the preview
Go deeper on 2020-001714-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001714-38.